WO2008070861A3 - Methods and compositions for treating systemic lupus erythematosus - Google Patents

Methods and compositions for treating systemic lupus erythematosus Download PDF

Info

Publication number
WO2008070861A3
WO2008070861A3 PCT/US2007/086861 US2007086861W WO2008070861A3 WO 2008070861 A3 WO2008070861 A3 WO 2008070861A3 US 2007086861 W US2007086861 W US 2007086861W WO 2008070861 A3 WO2008070861 A3 WO 2008070861A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
compositions
systemic lupus
lupus erythematosus
methods
treating systemic
Prior art date
Application number
PCT/US2007/086861
Other languages
French (fr)
Other versions
WO2008070861A2 (en )
Inventor
Julie Lynne Christensen
Original Assignee
Cellerant Therapeutics Inc
Julie Lynne Christensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Abstract

The present disclosure relates to compositions and method for treating a patient suffering from systemic lupus erythematosus and related conditions, comprising subjecting said patient to myeloablation and administering to said patient hematopoietic stem cells.
PCT/US2007/086861 2006-12-07 2007-12-07 Methods and compositions for treating systemic lupus erythematosus WO2008070861A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US86908506 true 2006-12-07 2006-12-07
US60/869,085 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008070861A2 true WO2008070861A2 (en) 2008-06-12
WO2008070861A3 true true WO2008070861A3 (en) 2008-07-24

Family

ID=39201592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086861 WO2008070861A3 (en) 2006-12-07 2007-12-07 Methods and compositions for treating systemic lupus erythematosus

Country Status (1)

Country Link
WO (1) WO2008070861A3 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210360A1 (en) * 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451611A2 (en) * 1990-03-30 1991-10-16 Sandoz Ltd Human hematopoietic stem cell
WO2003012060A2 (en) * 2001-08-01 2003-02-13 Jewish Hospital Healthcare Services, Inc. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451611A2 (en) * 1990-03-30 1991-10-16 Sandoz Ltd Human hematopoietic stem cell
WO2003012060A2 (en) * 2001-08-01 2003-02-13 Jewish Hospital Healthcare Services, Inc. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BRODSKY ROBERT A ET AL: "Hematopietic stem cell transplantation for systemic lupus erythematosus", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA, W.B. SAUNDERS, PHILADELPHIA, PA, US, vol. 26, no. 2, May 2000 (2000-05-01), pages 377 - 387, XP009098283, ISSN: 0889-857X *
BRYDER DAVID ET AL: "Hematopoietic stem cells: the paradigmatic tissue-specific stem cell.", THE AMERICAN JOURNAL OF PATHOLOGY AUG 2006, vol. 169, no. 2, August 2006 (2006-08-01), pages 338 - 346, XP002476779, ISSN: 0002-9440 *
BURT RICHARD K ET AL: "Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 1 FEB 2006, vol. 295, no. 5, 1 February 2006 (2006-02-01), pages 527 - 535, XP002475502, ISSN: 1538-3598 *
EL-BADRI NAGWA S ET AL: "Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 70, no. 6, 27 September 2000 (2000-09-27), pages 870 - 877, XP009098213, ISSN: 0041-1337 *
FOUILLARD L ET AL: "Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34 + purified autologous stem cells from peripheral blood", LUPUS, vol. 8, no. 4, 1999, pages 320 - 323, XP009098209, ISSN: 0961-2033 *
IKEHARA S ET AL: "LONG-TERM OBSERVATIONS OF AUTOIMMUNE-PRONE MICE TREATED FOR AUTOIMMUNE DISEASE BY ALLOGENEIC BONE MARROW TRANSPLANTATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 86, no. 9, 1989, pages 3306 - 3310, XP002475498, ISSN: 0027-8424 *
JONES OLCAY Y ET AL: "Nonmyeloablative bone marrow transplantation of BXSB lupus mice using fully matched allogeneic donor cells from green fluorescent protein transgenic mice", JOURNAL OF IMMUNOLOGY, vol. 172, no. 9, 1 May 2004 (2004-05-01), pages 5415 - 5419, XP002475499, ISSN: 0022-1767 *
LEVITE M ET AL: "Beneficial effects of bone marrow transplantation on the serological manifestations and kidney pathology of experimental systemic lupus erythematosus", CELLULAR IMMUNOLOGY, vol. 162, no. 1, 1995, pages 138 - 145, XP002475500, ISSN: 0008-8749 *
MUSSO M ET AL: "Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome", LUPUS, vol. 7, no. 7, 1998, pages 492 - 494, XP009098210, ISSN: 0961-2033 *
OYAMA Y ET AL: "Allogeneic stem cell transplantation for autoimmune diseases: Nonmyeloablative conditioning regimens.", BONE MARROW TRANSPLANTATION, vol. 32, no. Supplement 1, August 2003 (2003-08-01), pages S81 - S83, XP002475503, ISSN: 0268-3369 *
PETRI MICHELLE ET AL: "High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus.", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 1 FEB 2006, vol. 295, no. 5, 1 February 2006 (2006-02-01), pages 559 - 560, XP009098266, ISSN: 1538-3598 *
RICHARD BURT: "Allogeneic blood stem cell transplantation in Systemic Lupus Erythematosus", 16 January 2006 (2006-01-16), XP002476777, Retrieved from the Internet <URL:http://www.clinicaltrials.gov/ct2/show/NCT00278590?term=allogeneic+lupus&rank=1> [retrieved on 20080415] *
SHIZURU J.: "Allogeneic blood stem cell transplantation for patients with life-threatening Systemic Lupus Erythematosus", 12 May 2006 (2006-05-12), XP002476778, Retrieved from the Internet <URL:http://www.clinicaltrials.gov/ct2/show/NCT00325741?term=allogeneic+lupus&rank=2> [retrieved on 20080415] *
SHIZURU JUDITH A ET AL: "Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system.", ANNUAL REVIEW OF MEDICINE 2005, vol. 56, 2005, pages 509 - 538, XP002475497, ISSN: 0066-4219 *
SMITH-BERDAN STEPHANIE ET AL: "Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nom-nyeloablative transplantation of purified allogeneic hematopoietic stem cells", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 110, no. 4, August 2007 (2007-08-01), pages 1370 - 1378, XP009098269, ISSN: 0006-4971 *

Also Published As

Publication number Publication date Type
WO2008070861A2 (en) 2008-06-12 application

Similar Documents

Publication Publication Date Title
WO2005117557A3 (en) Expression system
WO2008070268A3 (en) Pharmaceutical compositions
WO2009089494A3 (en) Pharmaceutical compositions
WO2007134086A3 (en) Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2006097934A3 (en) Pancreas lead
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2007092622A3 (en) Compositions and methods for treating bone
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2009065738A3 (en) Polyoxyalkylenamines for improved fragrance yield
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2006083782A3 (en) Directed differentiation of embryonic stem cells and uses thereof
WO2008136394A1 (en) Method for production of lactam compound, and intermediate for the production method
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
WO2007143086A3 (en) Delivery method
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
GB0711726D0 (en) The Bioeden process for the isolation, culture and maintenance of tooth stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869054

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07869054

Country of ref document: EP

Kind code of ref document: A2